Slow and steady.
The hype around Ozempic is overblown. Side effects seem to be considered a serious affair with lots of cases of health issues and even deaths. No reason for a 30% sell off. Second quarter results should hopefully confirm what we've been thinking. Sales growth and revenues up, maybe a small hit to margins, but nothing too serious, certainly not to warrant a 30% decline.
- Forums
- ASX - By Stock
- RMD
- Ann: ResMed to Report Second Quarter Fiscal 2024 Results
Ann: ResMed to Report Second Quarter Fiscal 2024 Results, page-3
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RMD (ASX) to my watchlist
(20min delay)
|
|||||
Last
$32.52 |
Change
-0.860(2.58%) |
Mkt cap ! $20.90B |
Open | High | Low | Value | Volume |
$32.39 | $32.61 | $32.35 | $42.10M | 1.295M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 18385 | $32.50 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$32.53 | 8891 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 600 | 33.200 |
1 | 600 | 33.000 |
2 | 230 | 32.800 |
1 | 63 | 32.700 |
1 | 100 | 32.600 |
Price($) | Vol. | No. |
---|---|---|
31.480 | 500 | 2 |
31.530 | 45 | 1 |
32.000 | 167 | 2 |
32.490 | 1 | 1 |
32.500 | 2842 | 3 |
Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
Featured News
RMD (ASX) Chart |